Surmodics Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Los beneficios de Surmodics han disminuido a una tasa media anual de -52.1%, mientras que en la industria Medical Equipment los beneficios crecieron en un 13.5% anualmente. Los ingresos han ido creciendo a una tasa media de 6.2% al año. La rentabilidad financiera de Surmodics es de 4.5%, y sus márgenes netos son de 4%.

Información clave

-38.2%

Tasa de crecimiento de los beneficios

-38.4%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	8.9%
Tasa de crecimiento de los ingresos	7.0%
Rentabilidad financiera	10.9%
Margen neto	9.4%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital

May 02

We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt

Sep 17

News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts

Jun 26

An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued

Jun 22

Is Surmodics (NASDAQ:SRDX) A Risky Investment?

May 14

Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher

Apr 17

Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Feb 03

Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?

Jan 08

Surmodics gets additional $125M in credit facility

Oct 17

Surmodics Non-GAAP EPS of -$0.34 beats by $0.04, revenue of $24.9M misses by $0.29M

Jul 27

Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)

Jul 22

Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?

May 03

Shareholders May Not Be So Generous With Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation And Here's Why

Feb 04

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Surmodics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:SRDX Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	143	14	51	47
31 Dec 23	138	6	51	43
30 Sep 23	133	-2	52	47
30 Jun 23	131	-23	53	51
31 Mar 23	103	-36	53	51
31 Dec 22	102	-32	51	63
30 Sep 22	100	-27	47	51
30 Jun 22	98	-13	42	0
31 Mar 22	97	-10	37	0
31 Dec 21	106	2	34	0
30 Sep 21	105	4	32	49
30 Jun 21	104	2	30	-1
31 Mar 21	107	7	30	0
31 Dec 20	95	1	28	0
30 Sep 20	95	1	28	0
30 Jun 20	103	8	28	1
31 Mar 20	101	7	27	0
31 Dec 19	100	6	26	0
30 Sep 19	100	8	25	0
30 Jun 19	92	2	24	0
31 Mar 19	90	-2	23	0
31 Dec 18	87	-2	24	0
30 Sep 18	81	-4	23	0
30 Jun 18	78	-2	22	0
31 Mar 18	74	1	22	0
31 Dec 17	72	0	21	0
30 Sep 17	73	4	20	0
30 Jun 17	71	6	20	0
31 Mar 17	73	9	19	0
31 Dec 16	73	10	19	0
30 Sep 16	71	10	18	0
30 Jun 16	71	9	17	0
31 Mar 16	67	9	16	0
31 Dec 15	64	11	15	0
30 Sep 15	62	12	13	0
30 Jun 15	60	13	15	0
31 Mar 15	59	13	15	0
31 Dec 14	58	12	15	0
30 Sep 14	57	12	15	0
30 Jun 14	56	13	15	0
31 Mar 14	56	13	16	0
31 Dec 13	56	14	15	0
30 Sep 13	56	15	14	0
30 Jun 13	56	14	14	0

Ingresos de calidad: SRDX tiene ganancias de alta calidad.

Margen de beneficios creciente: SRDX pasó a ser rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: SRDX ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de -52.1% al año.

Acelerando crecimiento: SRDX ha pasado a ser rentable en el último año, lo que dificulta la comparación de la tasa de crecimiento de los beneficios con su promedio de 5 años.

Beneficios vs. Industria: SRDX ha pasado a ser rentable en el último año, lo que es difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Medical Equipment (3.3%).

Surmodics Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Información clave

Actualizaciones de resultados anteriores recientes

Second quarter 2024 earnings released: EPS: US$0.017 (vs US$0.55 loss in 2Q 2023)

Surmodics, Inc. to Report Q2, 2024 Results on May 01, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. to Report Q1, 2024 Results on Feb 01, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. to Report Q4, 2023 Results on Nov 08, 2023

Recent updates

Investor sentiment improves as stock rises 24%

Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year 2024

New major risk - Revenue and earnings growth

Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital

Second quarter 2024 earnings released: EPS: US$0.017 (vs US$0.55 loss in 2Q 2023)

Surmodics, Inc. to Report Q2, 2024 Results on May 01, 2024

Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. Announces Successful Early Clinical Use of its Pounce LP Thrombectomy System

Surmodics, Inc. to Report Q1, 2024 Results on Feb 01, 2024

Surmodics, Inc., Annual General Meeting, Feb 08, 2024

Insider exercised options and sold US$107k worth of stock

Surmodics, Inc. Announces 24-Month Data from the Swing Trial Presented At VEITHsymposium

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Surmodics, Inc. Announces Swing Trial 24-Month Data to Be Presented At Veith Symposium on November 15

Surmodics, Inc. Announces Launch of Preside Medical Device Coating Technology, Providing Lubricity and Durability to a Broader Range of Complex Device Applications

Surmodics, Inc. to Report Q4, 2023 Results on Nov 08, 2023

We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt

Consensus revenue estimates increase by 12%

Price target increased by 8.7% to US$59.50

Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year Ending September 30, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. to Report Q3, 2023 Results on Aug 02, 2023

News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts

Surmodics, Inc.(NasdaqGS:SRDX) dropped from Russell 2000 Growth-Defensive Index

An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued

Consensus revenue estimates increase by 11%

Surmodics, Inc. Receives FDA Approval for the SurVeil Drug-Coated Balloon

Surmodics Receives FDA 510(k) Clearance for Pounce LP Thrombectomy System

Is Surmodics (NASDAQ:SRDX) A Risky Investment?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher

Consensus EPS estimates upgraded to US$2.14 loss

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Surmodics, Inc. to Report Q1, 2023 Results on Feb 06, 2023

Consensus EPS estimates fall by 20%

Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil Drug-Coated Balloon

Price target decreased to US$61.00

Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?

Independent Director exercised options and sold US$64k worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Independent Director notifies of intention to sell stock

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Surmodics, Inc. Announces 24-Month Data from Its Transcend Clinical Trial At the Vascular InterVentional Advances

Surmodics, Inc. to Report Q4, 2022 Results on Nov 09, 2022

Surmodics, Inc. Announces TRANSCEND Trial 24-Month Data to be Presented at VIVA 2022

Surmodics gets additional $125M in credit facility

Surmodics, Inc. Announces 6-Month Data from the Surmodics SWING BTK First-in-Human Trial Presented at AMP Europe

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Surmodics, Inc. Updates Earnings Guidance for the Fiscal Year 2022

Surmodics Non-GAAP EPS of -$0.34 beats by $0.04, revenue of $24.9M misses by $0.29M

Insider exercised options and sold US$254k worth of stock

Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)

Surmodics, Inc. to Report Q3, 2022 Results on Jul 27, 2022

Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?

Price target increased to US$74.00

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. Revises Earnings Guidance for the Full Year Ended September 30, 2022

Insufficient new directors

Surmodics, Inc. to Report Q2, 2022 Results on Apr 27, 2022

Consensus EPS estimates fall by 26%

Key Executive notifies of intention to sell stock

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Desglose de ingresos y gastos
Beta